MISSISSAUGA, ON, April 26,
2023 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, today announced its attendance at the
48th Annual Canadian Vascular Access Association (CVAA)
Conference and World Congress on Vascular Access (WoCoVA) Special
Event from Wednesday, April 26 to
Friday, April 28, 2023 in
Toronto, Canada.
CVAA is the only Canadian national conference that brings
together infusion therapy and vascular access professionals in
Canada. WoCoVA aims to improve
vascular access for patients worldwide by promoting the science and
practice of vascular access. Through the WoCoVA network, national
societies like CVAA can share results of research, initiatives, and
innovations in vascular access with other specialists from all over
the globe.
"We are excited to participate in the CVAA Conference to share
information and help educate how our suite of vascular access
infection prevention solutions can help to improve the overall
patient care experience," said Ron
Hebert, Senior Vice President, Global Marketing, Covalon.
"Our products are made for patients but have been specifically
designed with the care providers that use them in mind."
Visit the Covalon booth to learn more about the company's
vascular access and infection prevention solutions, and how Covalon
is focused on compassionate care tech that benefits both patients
and care providers. To schedule an appointment with a Covalon
representative at this event, please email rhebert@covalon.com.
Conference Details
Dates: Wednesday, April 26 to
Friday, April 28, 2023
Venue: Sheraton Centre Toronto Hotel (123 Queen St W, Toronto, Ontario, Canada)
Register at:
https://cvaa.info/en/news-events/event-calendar/pageid/signuptoevent/eventid/337/e/48th-annual-cvaa-conference-wocova-special-event-26-apr-2023
Covalon's vascular access infection prevention solutions help to
prevent central line-associated bloodstream infections (CLABSIs) as
part of an effective CLABSI prevention bundle, while ensuring
patient comfort and include:
- CovaClear® IV – utilizes soft silicone adhesive
technology to help protect patients from skin injuries, but does
not incorporate antimicrobials, for use with patients who either
don't require or cannot tolerate antimicrobials.
- IV Clear® - the world's only dual-antimicrobial
vascular access dressing that offers complete transparency at and
around the insertion site for easy daily assessment. It also
utilizes soft silicone adhesive technology to minimize skin
injuries and preserve skin barrier functions, and incorporates safe
amounts of antimicrobials, without sacrificing efficacy, to protect
against chemical irritation.
- VALGuard® - an FDA listed, transparent,
environmental barrier designed to protect catheter hubs and line
connections from external contaminants and gross contamination,
including body fluids and other secretions. It incorporates a
quick-release pull strip for fast access to infusion hubs and for
easy removal.
For healthcare providers who are not able to attend the
conference but are interested in learning more about Covalon's
solutions, visit www.covalon.com or follow Covalon on
LinkedIn, Facebook, Instagram or Twitter.
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device
company, built on the relentless pursuit to help the most
vulnerable patients have a better chance at healing. Through a
strong portfolio of patented technologies and solutions for
advanced wound care, infection prevention, and medical device
coatings, we offer innovative, gentler, and more compassionate
options for patients to heal with less infections, less pain, and
better outcomes. Our solutions are designed for patients and made
for care providers. Covalon leverages its patented medical
technology platforms and expertise in two ways: (i) by developing
products that are sold under Covalon's name; and (ii) by developing
and commercializing medical products for other medical companies
under development and license contracts. The Company is listed on
the TSX Venture Exchange, having the symbol COV and trades on the
OTCQX Market under the symbol CVALF. To learn more about Covalon,
visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results "may",
"could", "would", "might", "will" or "will be taken", "occur", or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which
is available on the Company's profile at
www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/compassionate-care-solutions-provider-covalon-participating-in-the-canadian-vascular-access-association-and-world-congress-on-vascular-access-joint-conference-on-april-26-28-2023-in-toronto-301808351.html
SOURCE Covalon Technologies Ltd.
